Cells that are about to die send a signal to an executioner protein, but sometimes, those cells can fight back and regenerate ...
The Immune Atlas identifies immune signatures in MM, enhancing outcome prediction and guiding personalized therapies by ...
Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...
Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
Lymphatic malformations (LMs) are congenital vascular anomalies characterized by abnormal lymphatic development, leading to ...
Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008)7-year ...
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
The Warburg effect describes how cancer cells switch from oxidative phosphorylation to glycolysis even in oxygen-rich conditions, producing massive amounts of lactate that accumulate in the tumor ...
Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback